1
Kevin Rodzinak
Arruda Jeannie M, Campbell Brian T, Cosford Nicholas D P, Hoffman Jacob M, Hu Essa H, Layton Mark E, Li Yiwei, Liang Jun, Rodzinak Kevin J, Siu Tony, Stearns Brian A, Tehrani Lida R: Inhibitors of akt activity. Merck & Co, Arruda Jeannie M, Campbell Brian T, Cosford Nicholas D P, Hoffman Jacob M, Hu Essa H, Layton Mark E, Li Yiwei, Liang Jun, Rodzinak Kevin J, Siu Tony, Stearns Brian A, Tehrani Lida R, MERCK 126 East Lincoln Avenue Rahway NJ 07065 0907, June 22, 2006: WO/2006/065601 (23 worldwide citation)

The present invention is directed to compounds which contain substituted naphthyridines which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer ...


2
Stéphane De Lombaert
Bakthavatchalam Rajagopal, Blum Charles A, Brielmann Harry, Chenard Bertrand L, de, Lombaert Stéphane, Hodgetts Kevin J, Hutchison Alan, Yoon Taeyoung, Zheng Xiaozhang: Biaryl piperazinyl-pyridine analogues. Neurogen Corporation, Bakthavatchalam Rajagopal, Blum Charles A, Brielmann Harry, Chenard Bertrand L, de, Lombaert Stéphane, Hodgetts Kevin J, Hutchison Alan, Yoon Taeyoung, Zheng Xiaozhang, ALEXANDER John B, January 27, 2005: WO/2005/007648 (17 worldwide citation)

Biaryl piperazinyl -pyri dine analogues are provided, of the Formula (I): wherein variables are as described herein. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with path ...


3
Stéphane De Lombaert
Rajagopal Bakthavatchalam, Charles A Blum, Stéphane De Lombaert, Taeyoung Yoon, Xiaozhang Zheng: Biaryl piperazinyl-pyridine analogues. Neurogen Corporation, Edwards Angell Palmer & Dodge, Peter F Corless, Mark D Russett, July 28, 2009: US07566712 (6 worldwide citation)

Biaryl piperazinyl-pyridine analogues are provided, of the Formula: wherein variables are as described herein. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathologic ...


4
Stéphane De Lombaert
Rajagopal Bakthavatchalam, Charles A Blum, Harry Brielmann, Timothy M Caldwell, Stéphane De Lombaert, Kevin J Hodgetts, Xiaozhang Zheng, Taeyoung Yoon: Substituted quinazolin-4-ylamine analogues. Neurogen Corporation, Edwards Angell Palmer & Dodge, Peter F Corless, Mark D Russett, December 4, 2007: US07304059 (3 worldwide citation)

Substituted quinazolin-4-ylamine analogues are provided. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated compani ...


5
Kevin Rodzinak
Vadim Y Dudkin, Mark E Fraley, Kenneth L Arrington, Mark E Layton, Alexander J Reif, Kevin J Rodzinak, Joseph E Pero: Positive allosteric modulators of MGLUR2. Merck Sharp & Dohme, Keith D MacMillan, John C Todaro, March 31, 2015: US08993779 (1 worldwide citation)

The present invention is directed to benzimidazolone derivatives which are positive allosteric modulators of the mGluR2 receptor, useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 receptor is involve ...


6
Stéphane De Lombaert
CHEN Zhidong, DE LOMBAERT Stéphane, DINES Jonathon Alan, LIU Weimin, LO Ho Yin, LOKE Pui Leng: INHIBITEURS BENZIMIDAZOLES DE LA PRODUCTION DE LEUCOTRIÈNES, BENZIMIDAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION. BOEHRINGER INGELHEIM INTERNATIONAL, CHEN Zhidong, DE LOMBAERT Stéphane, DINES Jonathon Alan, LIU Weimin, LO Ho Yin, LOKE Pui Leng, MORRIS Michael P, May 3, 2012: WO/2012/058254

The present invention relates to compounds of formula IA and IB and pharmaceutically acceptable salts thereof, wherein R1-R7 are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various disea ...


7
Kevin Rodzinak
Hidetomo Furuyama, Yasuhiro Goto, Nobuhiko Kawanishi, Mark E Layton, Takashi Mita, Akira Naya, Yoshio Ogino, Yu Onozaki, Kevin J Rodzinak, Toshihiro Sakamoto, Philip E Sanderson, Jiabing Wang: Inhibitors of akt activity. April 21, 2011: US20110092511-A1

The instant invention provides for substituted naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms, preferably Akt1. The invention also provides for compositions comprising such inhibitory compounds and methods ...


8
Kevin Rodzinak
Arruda Jeannie M, Campbell Brian T, Cosford Nicholas D P, Hoffman Jacob M, Hu Essa H, Layton Mark E, Li Yiwei, Liang Jun, Rodzinak Kevin J, Siu Tony, Stearns Brian A, Tehrani Lida R: Inhibitors of akt activity. Merck &Amp Co, wenhong yan liangmou, August 13, 2008: CN200580043064

The present invention is directed to compounds which contain substituted naphthyridines which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer ...


9
Prabhu Mohapatra
Laxminarayan Bhat, Prabhu Prasad Mohapatra, Kouacou Adiey: Methods of utilizing arylpiperazine derivatives. Reviva Pharmaceuticals, Perkins Coie, Viola T Kung, October 14, 2014: US08859552

The present invention provides arylpiperazine derivatives which can be advantageously used for treating schizophrenia and related psychoses such as acute manic, bipolar disorder, autistic disorder, and depression.


10
Carini David John, Duncia John Jonas Vytautas: Angiotensin ii receptor blocking imidazoles.. Du Pont, January 20, 1988: EP0253310-A2 (316 worldwide citation)

Substituted imidazoles such as are useful as angiotensin II blockers. These compounds have activity in treating hypertension and congestive heart failure.